These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32937648)

  • 21. Faecal microbiota signatures of IBD and their relation to diagnosis, disease phenotype, inflammation, treatment escalation and anti-TNF response in a European Multicentre Study (IBD-Character).
    Vatn S; Carstens A; Kristoffersen AB; Bergemalm D; Casén C; Moen AEF; Tannaes TM; Lindstrøm J; Detlie TE; Olbjørn C; Lindquist CM; Söderholm JD; Gomollón F; Kalla R; Satsangi J; Vatn MH; Jahnsen J; Halfvarson J; Ricanek P;
    Scand J Gastroenterol; 2020 Oct; 55(10):1146-1156. PubMed ID: 32780604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum ST2 in inflammatory bowel disease: a potential biomarker for disease activity.
    Boga S; Alkim H; Koksal AR; Ozagari AA; Bayram M; Tekin Neijmann S; Sen I; Alkim C
    J Investig Med; 2016 Jun; 64(5):1016-24. PubMed ID: 27001944
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.
    Canani RB; Terrin G; Rapacciuolo L; Miele E; Siani MC; Puzone C; Cosenza L; Staiano A; Troncone R
    Dig Liver Dis; 2008 Jul; 40(7):547-53. PubMed ID: 18358796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease.
    Walkiewicz D; Werlin SL; Fish D; Scanlon M; Hanaway P; Kugathasan S
    Inflamm Bowel Dis; 2008 May; 14(5):669-73. PubMed ID: 18240279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
    Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease.
    Zhulina Y; Cao Y; Amcoff K; Carlson M; Tysk C; Halfvarson J
    Aliment Pharmacol Ther; 2016 Sep; 44(5):495-504. PubMed ID: 27402063
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utility of faecal calprotectin analysis in adult inflammatory bowel disease.
    Smith LA; Gaya DR
    World J Gastroenterol; 2012 Dec; 18(46):6782-9. PubMed ID: 23239916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of two immunoassays for measurement of faecal calprotectin in detection of inflammatory bowel disease: (pre)-analytical and diagnostic performance characteristics.
    Oyaert M; Trouvé C; Baert F; De Smet D; Langlois M; Vanpoucke H
    Clin Chem Lab Med; 2014 Mar; 52(3):391-7. PubMed ID: 24114912
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fecal lactoferrin, a marker of intestinal inflammation in children with inflammatory bowel disease.
    Borkowska A; Liberek A; Łuczak G; Jankowska A; Plata-Nazar K; Korzon M; Kamińska B
    Acta Biochim Pol; 2015; 62(3):541-5. PubMed ID: 26339799
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rectal mucosal nitric oxide in differentiation of inflammatory bowel disease and irritable bowel syndrome.
    Reinders CI; Herulf M; Ljung T; Hollenberg J; Weitzberg E; Lundberg JO; Hellström PM
    Clin Gastroenterol Hepatol; 2005 Aug; 3(8):777-83. PubMed ID: 16234006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
    Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
    World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differentiation Between Pediatric Irritable Bowel Syndrome and Inflammatory Bowel Disease Based on Fecal Scent: Proof of Principle Study.
    Bosch S; van Gaal N; Zuurbier RP; Covington JA; Wicaksono AN; Biezeveld MH; Benninga MA; Mulder CJ; de Boer NKH; de Meij TGJ
    Inflamm Bowel Dis; 2018 Oct; 24(11):2468-2475. PubMed ID: 29788410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The microbiome reflects diagnosis and predicts disease severity in paediatric onset inflammatory bowel disease.
    Malham M; Lilje B; Houen G; Winther K; Andersen PS; Jakobsen C
    Scand J Gastroenterol; 2019 Aug; 54(8):969-975. PubMed ID: 31329473
    [No Abstract]   [Full Text] [Related]  

  • 34. Faecal gas analysis by electronic nose as novel, non-invasive method for assessment of active and quiescent paediatric inflammatory bowel disease: Proof of principle study.
    de Meij TG; de Boer NK; Benninga MA; Lentferink YE; de Groot EF; van de Velde ME; van Bodegraven AA; van der Schee MP
    J Crohns Colitis; 2014 Sep; ():. PubMed ID: 25248313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of faecal immunochemical testing as an alternative to faecal calprotectin in children.
    Sandhu K; Naik S; Ayling RM
    Ann Clin Biochem; 2021 May; 58(3):230-235. PubMed ID: 33412889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Research advances on B-cell activating factor and its targeted agents in inflammatory bowel disease].
    Li L; Liu HY; Wang LJ
    Zhongguo Dang Dai Er Ke Za Zhi; 2024 Mar; 26(3):315-320. PubMed ID: 38557386
    [TBL] [Abstract][Full Text] [Related]  

  • 37. B-cell activating factor (BAFF) expression is associated with Crohn's disease and can serve as a potential prognostic indicator of disease response to Infliximab treatment.
    Andreou NP; Legaki E; Dovrolis N; Boyanov N; Georgiou K; Gkouskou K; Gazouli M
    Dig Liver Dis; 2021 May; 53(5):574-580. PubMed ID: 33339749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum galectins as potential biomarkers of inflammatory bowel diseases.
    Yu TB; Dodd S; Yu LG; Subramanian S
    PLoS One; 2020; 15(1):e0227306. PubMed ID: 31929564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
    Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic interleukin-9 in inflammatory bowel disease: Association with mucosal healing in ulcerative colitis.
    Matusiewicz M; Neubauer K; Bednarz-Misa I; Gorska S; Krzystek-Korpacka M
    World J Gastroenterol; 2017 Jun; 23(22):4039-4046. PubMed ID: 28652656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.